Guggenheim Capital LLC Cassava Sciences Inc Transaction History

Guggenheim Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $18,322 - $40,932	-1,064 Reduced 3.45%	29,808 $839,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $129,552 - $210,820	-3,974 Reduced 11.4%	30,872 $1.15 Million
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $336,408 - $831,735	9,149 Added 35.6%	34,846 $1.52 Million
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $1.07 Million - $3.48 Million	25,697 New	25,697 $1.6 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.